Literature DB >> 11057932

Antiretroviral therapy for drug users.

S M Clarke1, F M Mulcahy.   

Abstract

Injection drug use represents the primary risk factor for up to 40% of patients with HIV infection. Physicians are generally reluctant to prescribe antiretroviral therapy (ART) for these patients due to possible poor adherence, and the potential for complex drug interactions to occur. Providing daily observed ART in conjunction with methadone maintenance therapy (MMT) has significantly improved accessibility of ART for many drug users. Knowledge of potential drug interactions between methadone, ART, and both legally and illegally prescribed drugs has permitted such interactions to be anticipated and either avoided or treated appropriately. Optimizing ART for drug users therefore demands a multidisciplinary approach from medical, clinical pharmacology and psychiatric services.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11057932     DOI: 10.1258/0956462001914913

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  3 in total

1.  Associations among correlates of schedule adherence to antiretroviral therapy (ART): a path analysis of a sample of crack cocaine using sexually active African-Americans with HIV infection.

Authors:  J S Atkinson; L Nilsson Schönnesson; M L Williams; S C Timpson
Journal:  AIDS Care       Date:  2008-02

2.  Does initiation of HIV antiretroviral therapy influence patterns of syringe lending among injection drug users?

Authors:  Laura Kuyper; M-J Milloy; Brandon D L Marshall; Ruth Zhang; Thomas Kerr; Julio S G Montaner; Evan Wood
Journal:  Addict Behav       Date:  2011-01-21       Impact factor: 3.913

3.  Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy.

Authors:  Anita Palepu; Mark W Tyndall; Kathy Li; Benita Yip; Michael V O'Shaughnessy; Martin T Schechter; Julio S G Montaner; Robert S Hogg
Journal:  J Urban Health       Date:  2003-12       Impact factor: 3.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.